Evommune (EVMN) Revenue & Revenue Breakdown
Evommune Revenue Highlights
Latest Revenue (Y)
$13.00M
Evommune Revenue by Period
Evommune Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $13.00M | 85.71% |
| 2024-12-31 | $7.00M | 40.00% |
| 2023-12-31 | $5.00M | - |
Evommune generated $13.00M in revenue during NA 2025, up 85.71% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Evommune Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-03-31 | - | 100.00% |
| 2025-12-31 | - | -100.00% |
| 2025-09-30 | $10.00M | 100.00% |
| 2025-06-30 | - | -100.00% |
| 2025-03-31 | $3.00M | 100.00% |
| 2024-12-31 | - | 100.00% |
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $7.00M | - |
Evommune generated - in revenue during Q1 2026, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Evommune Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FTRE | Fortrea | $2.72B | $636.50M |
| LGND | Ligand Pharmaceuticals | $268.09M | $51.72M |
| GLPG | Galapagos | $239.70M | $62.43M |
| KPTI | Karyopharm Therapeutics | $146.07M | $35.07M |
| CDXS | Codexis | $70.39M | $15.25M |
| EYPT | EyePoint Pharmaceuticals | $31.37M | $696.00K |
| OABI | OmniAb | $18.67M | $14.43M |
| EVMN | Evommune | $13.00M | - |
| ARTV | Artiva Biotherapeutics | - | - |
| CLYM | Climb Bio | - | - |
| ZYME | Zymeworks | $-27.11M | - |